Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population

Area of Science:

• Clinical Medicine
• Psychiatry
• Pharmacology

Background:

• Opioid dependence is a chronic relapsing disease.
• Sleep disturbances and depression are common comorbidities in opioid use disorder.
• Medication-assisted treatment (MAT) is a standard of care for opioid dependence.

Purpose of the Study:

• To evaluate patient-reported sleep and depression outcomes in early recovery.
• To assess the impact of buprenorphine/naloxone MAT on sleep and depressive symptoms.
• To examine changes over a 90-day treatment period.

Main Methods:

• Prospective, naturalistic study design.
• Recruited 40 subjects with opioid dependence disorder initiating buprenorphine/naloxone MAT.
• Administered MOS-Sleep, Supplemental Sleep Scale (SSS), and Beck Depression Inventory II (BDI-II) at baseline, 30, 60, and 90 days.

Main Results:

• Significant progressive improvements in MOS-Sleep subscales for sleep disturbance, Sleep Problem Index I, and Sleep Problem Index II.
• Mean sleep disturbance scores decreased from 62.4 at baseline to 48.4 at 90 days (p=0.0029).
• Beck Depression Inventory II scores improved from moderate to mild depression, with mean scores decreasing from 24.2 to 17.0 (p<0.05).

Conclusions:

• Initiating MAT with buprenorphine/naloxone is associated with significant improvements in sleep quality.
• Buprenorphine/naloxone treatment also leads to a reduction in depressive symptoms.
• These findings support the efficacy of MAT in addressing sleep and mood disturbances in opioid dependence recovery.